Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan: Report from the chart-2 study

Circulation Journal

Volumn 78, Issue 2, 2014, Pages 428-435

  Sakata, Yasuhiko ^a   Miyata, Satoshi ^a   Nochioka, Kotaro ^a   Miura, Masanobu ^a   Takada, Tsuyoshi ^a   Tadaki, Soichiro ^a   Takahashi, Jun ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gender difference; Heart failure; Observational study; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; SEX DIFFERENCE; SURVIVAL RATE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; EPIDEMIOLOGY; HEART INFARCTION; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SEXUAL DEVELOPMENT; SMOKING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PREVALENCE; RISK FACTORS; SEX CHARACTERISTICS; SMOKING;

EID: 84893022772     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1009     Document Type: Article

References (27)

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. Natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971; 285: 1441-1446.
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
3. Adams KF, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996; 28: 1781-1788.
4. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
5. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350.
6. Pina IL. A better survival for women with heart failure? It's not so simple. J Am Coll Cardiol 2003; 42: 2135-2138.
7. Adams KF, Sueta CA, Gheorghiade M, O'Connor CM, Schwartz TA, Koch GG, et al. Gender differences in survival in advanced heart failure: Insights from the FIRST study. Circulation 1999; 99: 1816-1821.
8. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, et al. Gender differences in advanced heart failure: Insights from the BEST study. J Am Coll Cardiol 2003; 42: 2128-2134.
9. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, et al.; CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 115: 3111-3120.
10. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (IPRESERVE) trial. Circ Heart Fail. 2012; 5: 571-578.
11. Deswal A, Bozkurt B. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 2006; 97: 1228-1231.
12. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209-2217.
13. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. Circ J 2011; 75: 823-833.
14. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, et al; CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. Eur J Heart Fail 2012; 14: 367-376.
15. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, et al; CHART-2 Investigators. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: A report from the CHART-2 Study. Circ J 2013; 77: 2318-2326.
16. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, et al.; CHART-2 Investigators. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure: A report from the CHART-2 Study. Circ J 2013; 77: 2954-2962.
17. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
18. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM Preserved Trial. Lancet 2003; 362: 777-781.
19. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345.
20. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
21. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
22. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
23. Farasat SM, Bolger DT, Shetty V, Menachery EP, Gerstenblith G, Kasper EK, et al. Effect of beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am J Cardiol 2010; 105: 229-234.
24. Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118.
25. Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, et al; PEARL Study Investigators. Effects of pitavastatin in Japanese patients with chronic heart failure: The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-925.
26. Kihara Y. Statin therapy in chronic heart failure: Frog prince or bare frog? Circ J 2013; 77: 895-897.
27. Ministry of Health, Labour and Welfare of Japan. Complete Life Table. http://www.mhlw.go.jp/toukei/saikin/hw/life/21th/index.html (accessed 25 November, 2013).